4D Pharma's 'breakthrough' IBS treatment approaches phase II clinical trial — 3 key notes

4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial, The Press and Journal reports.

Here's what you should know:

1. Blautix completed a phase I trial last year, showing it was both safe and well tolerated by patients.

2. 4D Pharma researchers said their research claims the microbiome causes or exacerbates IBS.

3. Blautix uses live bacteria to treat irritable bowel syndrome by reacting with bacteria present in the microbiome.

More articles on gastroenterology: 
GI leader to know: Dr. Erick Singh of Consultants in Gastroenterology
'Relentless dedication to IBD care' — How 3 GI leaders will use their Sherman Prizes to enhance IBD, Crohn's treatment
Creo Medical's device receives FDA 510(k) approval & more — 6 GI company key notes

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months